JP7406672B2 - ニコチンアミド系ｒｉｐｋ１阻害剤 - Google Patents

ニコチンアミド系ｒｉｐｋ１阻害剤 Download PDF

Info

Publication number
JP7406672B2
JP7406672B2 JP2023516136A JP2023516136A JP7406672B2 JP 7406672 B2 JP7406672 B2 JP 7406672B2 JP 2023516136 A JP2023516136 A JP 2023516136A JP 2023516136 A JP2023516136 A JP 2023516136A JP 7406672 B2 JP7406672 B2 JP 7406672B2
Authority
JP
Japan
Prior art keywords
mmol
hydrogen
methyl
mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023516136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549007A (ja
Inventor
キューザック，ケビン・パトリック
ホエマン，マイケル・ゼラー
キンズマン，デイビッド・アンドルー
オスマン，サミ
スタンブリ，ジェームズ・パトリック
アージリアディ，マリア・アナスタシア
オレイリー，シアラン
デクスター，ハンナ
フォーダイス，ユアン
セント・ギャラリー，スティーブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2023549007A publication Critical patent/JP2023549007A/ja
Priority to JP2023210859A priority Critical patent/JP2024037892A/ja
Application granted granted Critical
Publication of JP7406672B2 publication Critical patent/JP7406672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
JP2023516136A 2021-08-10 2022-08-08 ニコチンアミド系ｒｉｐｋ１阻害剤 Active JP7406672B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023210859A JP2024037892A (ja) 2021-08-10 2023-12-14 ニコチンアミド系ｒｉｐｋ１阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163231590P 2021-08-10 2021-08-10
US63/231,590 2021-08-10
PCT/US2022/039689 WO2023018643A1 (en) 2021-08-10 2022-08-08 Nicotinamide ripk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023210859A Division JP2024037892A (ja) 2021-08-10 2023-12-14 ニコチンアミド系ｒｉｐｋ１阻害剤

Publications (2)

Publication Number Publication Date
JP2023549007A JP2023549007A (ja) 2023-11-22
JP7406672B2 true JP7406672B2 (ja) 2023-12-27

Family

ID=83439074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023516136A Active JP7406672B2 (ja) 2021-08-10 2022-08-08 ニコチンアミド系ｒｉｐｋ１阻害剤
JP2023210859A Pending JP2024037892A (ja) 2021-08-10 2023-12-14 ニコチンアミド系ｒｉｐｋ１阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023210859A Pending JP2024037892A (ja) 2021-08-10 2023-12-14 ニコチンアミド系ｒｉｐｋ１阻害剤

Country Status (15)

Country Link
US (2) US11767310B2 (cg-RX-API-DMAC10.html)
EP (2) EP4643949A3 (cg-RX-API-DMAC10.html)
JP (2) JP7406672B2 (cg-RX-API-DMAC10.html)
KR (2) KR102707109B1 (cg-RX-API-DMAC10.html)
CN (1) CN117460722A (cg-RX-API-DMAC10.html)
AR (1) AR126733A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022328136A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025850A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219155A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023017151A2 (cg-RX-API-DMAC10.html)
IL (1) IL308349A (cg-RX-API-DMAC10.html)
MX (1) MX2023014817A (cg-RX-API-DMAC10.html)
TW (1) TW202321211A (cg-RX-API-DMAC10.html)
WO (1) WO2023018643A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310682B (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321211A (zh) 2021-08-10 2023-06-01 美商艾伯維有限公司 菸鹼醯胺ripk1抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020149553A1 (ko) 2019-01-15 2020-07-23 주식회사 보로노이 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
JP2021530467A (ja) 2018-07-02 2021-11-11 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. キナーゼ活性を阻害するためのアルキニル（ヘテロ）芳香族化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005131A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New carboxamides with antifungal activity
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
CA2533889A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7465746B2 (en) 2003-08-15 2008-12-16 Merck & Co., Inc. Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP
US7112316B1 (en) 2005-08-08 2006-09-26 Uop Llc Process for preparing molecular sieves via continuous addition of nutrients
EP1984355A2 (en) 2006-02-16 2008-10-29 Takeda Pharmaceutical Company Limited Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
ATE505454T1 (de) 2007-09-20 2011-04-15 Amgen Inc 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
WO2011113707A1 (en) 2010-03-17 2011-09-22 Exxonmobil Chemical Patents Inc. Plasticiser blends and compositions and articles made therefrom
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
WO2013049255A1 (en) 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
EA032355B1 (ru) 2013-12-24 2019-05-31 Онкотартис, Инк. Бензамидные и никотинамидные соединения и способы их применения
KR101555033B1 (ko) 2014-07-28 2015-09-23 충남대학교산학협력단 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3224237B1 (en) 2014-12-24 2024-09-11 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
EP3515447A4 (en) 2016-09-26 2020-05-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
DE102017211104B3 (de) 2017-06-29 2018-10-18 Bundesdruckerei Gmbh Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung
CN111566103B (zh) * 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) * 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
WO2020013531A1 (ko) 2018-07-10 2020-01-16 보로노이바이오 주식회사 N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
TW202321211A (zh) 2021-08-10 2023-06-01 美商艾伯維有限公司 菸鹼醯胺ripk1抑制劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530467A (ja) 2018-07-02 2021-11-11 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. キナーゼ活性を阻害するためのアルキニル（ヘテロ）芳香族化合物
WO2020149553A1 (ko) 2019-01-15 2020-07-23 주식회사 보로노이 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물

Also Published As

Publication number Publication date
MX2023014817A (es) 2024-01-12
ZA202310682B (en) 2024-08-28
CN117460722A (zh) 2024-01-26
EP4301744A1 (en) 2024-01-10
EP4643949A2 (en) 2025-11-05
AR126733A1 (es) 2023-11-08
TW202321211A (zh) 2023-06-01
AU2022328136A1 (en) 2023-11-30
JP2024037892A (ja) 2024-03-19
KR20230163568A (ko) 2023-11-30
JP2023549007A (ja) 2023-11-22
US20230127127A1 (en) 2023-04-27
IL308349A (en) 2024-01-01
CA3219155A1 (en) 2023-02-16
KR20240135076A (ko) 2024-09-10
EP4643949A3 (en) 2026-01-07
US11767310B2 (en) 2023-09-26
US20240360099A1 (en) 2024-10-31
WO2023018643A1 (en) 2023-02-16
BR112023025850A2 (pt) 2024-03-05
CO2023017151A2 (es) 2023-12-29
KR102707109B1 (ko) 2024-09-20

Similar Documents

Publication Publication Date Title
EP3728223B1 (en) Cyclohexyl acid triazole azines as lpa antagonists
EP3710438B1 (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3712153B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CN114269755A (zh) 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
WO2020060915A1 (en) Cyclopentyl acids as lpa antagonists
CN114599648A (zh) 作为lpa拮抗剂的三唑羧酸
KR20130133051A (ko) 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
EP3728240A1 (en) Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
BR112015020772B1 (pt) Compostos de pirimidina e piridina e seu uso
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
JP6858252B2 (ja) ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用
CN114634512B (zh) 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
WO2012173174A1 (ja) アザスピロアルカン化合物
JP2024037892A (ja) ニコチンアミド系ｒｉｐｋ１阻害剤
WO2024233812A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
JP7494222B2 (ja) ピリジン－３－イル誘導体
CN114286813A (zh) 取代的脲二氢乳清酸脱氢酶抑制剂
JP7447098B2 (ja) アミノピリミジン化合物
JP2014118368A (ja) アザスピロアルカン化合物を有効成分として含有する血糖低下作用薬
TW201617314A (zh) 羧酸衍生物
HK40072763A (en) Substituted urea dihydroorotate dehydrogenase inhibitors
HK40062310A (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
HK40002867B (en) Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231215

R150 Certificate of patent or registration of utility model

Ref document number: 7406672

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150